Effectiveness of vildagliptin versus other oral antidiabetes drugs as add-on to sulphonylurea monotherapy: Post hoc analysis from the EDGE study
- Resource Type
- Authors
- Helmut Brath; U Phadke; K M Prasanna Kumar; Chantal Mathieu; Päivi M. Paldánius; A Gawai
- Source
- Subject
- Blood Glucose
Male
Pyrrolidines
Time Factors
Endocrinology, Diabetes and Metabolism
Administration, Oral
Adamantane
030204 cardiovascular system & hematology
Weight Gain
0302 clinical medicine
Risk Factors
Odds Ratio
Clinical endpoint
Vildagliptin
Prospective Studies
Prospective cohort study
Nutrition and Dietetics
Sulphonylurea
Middle Aged
Metformin
Treatment Outcome
Tolerability
Drug Therapy, Combination
Female
Family Practice
medicine.drug
Adult
medicine.medical_specialty
India
030209 endocrinology & metabolism
03 medical and health sciences
Internal medicine
Diabetes mellitus
Nitriles
Post-hoc analysis
Internal Medicine
medicine
Humans
Hypoglycemic Agents
Real-life setting
Aged
Glycated Hemoglobin
Dipeptidyl-Peptidase IV Inhibitors
business.industry
Odds ratio
medicine.disease
Logistic Models
Sulfonylurea Compounds
Endocrinology
Diabetes Mellitus, Type 2
Hyperglycemia
Multivariate Analysis
business
Biomarkers
- Language
- English
AimIn this post hoc analysis of the EDGE study, we assessed the effectiveness and safety of vildagliptin versus other oral antidiabetes drugs (OADs) as add-on to first-line sulphonylurea (SU) therapy in patients who did not receive metformin in a real-life setting.MethodsThe primary endpoint was odds of achieving an HbA1c reduction of >0.3% without tolerability issues. Secondary endpoint was odds of achieving HbA1c